1. The hepatitis B antigen-antibody complex vaccine “Bq”, which was developed by Fudan University and Beijing Institute of Biological Products, is one of them. The vaccine is a protein vaccine that combines HBV surface antigen and high-efficiency hepatitis B immunoglobulin in a certain ratio to form an antigen-antibody complex for the treatment of chronic hepatitis B. The project is led by academician Wen Yumei of Fudan University, and is the most systematic and in-depth research in China, and has been in phase III clinical trials for nearly 20 years. 2. The therapeutic hepatitis B vaccine jointly developed by the Third Military Medical University and Chongqing Brewery Company is a peptide biologic product based on the principle of molecular epitope design, which is synthesized by imitating certain peptide chains of hepatitis B antigen to induce cells to produce antibodies, and is a peptide vaccine. The project is led by Professor Wu Yuzhang of the Third Military Medical University and is also currently undergoing phase II clinical trials. 3. The therapeutic hepatitis B vaccine researched by Prof. Yijun Zhang of Guangzhou Air Force Hospital in cooperation with Shenzhen Kangtai Bio and the therapeutic DNA vaccine researched by the scientific collaborative group led by Guangming Chen were approved for Phase II clinical study.